Holland and Belgium becomes direct sales markets for all Allenex products from May 1st 2012.
As a part of Allenex (STO:ALNX) focus to build a global transplantation technology company with a strong sales and support organization the company now choose to sell directly to end customers in Holland and Belgium. The cooperation with the present distributor, Genome Products BV is terminated and Allenex will sell through its own sales organization, Olerup GmbH, starting May 1st, 2012.
"This change is in line with the company strategy and the transformation of Allenex into a pure transplantation technology company continues", says Allenex CEO Anders Karlsson. "As Allenex continue to grow our sales of transplantation technology products we view it as a natural step to sell through our own organization on more markets. The goal is to give customers a better service for all our products and thus increase sales. As a result we achieve better control, local influence and increased sales margins".
Allenex has already a high market share for the Olerup SSP HLA typing products in Benelux. This increased sales effort mean that Allenex new products will gain increased sales power.
Allenex sells today directly to end customers in the Nordic countries, Germany, Austria, Slovenia and in the USA. From May 1st 2012 also in Holland and Belgium. Other markets are handled via distributors.
Allenex AB discloses the information provided herein pursuant to the Securities Markets Act And/or the Financial Instruments Trading Act. The information was submitted for publication on April 27, 2012, at 08.40 CET.
Allenex is a life science company that develops, manufactures and markets products and services for safer transplantations. Allenex is listed on NASDAQ OMX Stockholm Small Cap (ticker: ALNX). 54 persons are employed in the Allenex group.
This information was brought to you by Cision http://www.cisionwire.com
Anders Karlsson, CEO
tel: +46 709 18 00 10